An overlooked mental health challenge faced by new mothers. A powerful new drug could be critical in fighting back. It should have been an obvious match. Yet things may not turn out that way because of pharma industry’s pricing vagaries as well as the lack of conversation around the condition itself.
Related Posts
Lifesaver to litigant: how a Covid-19 drug drove a wedge between Max Healthcare and Novacare
Synopsis Ronapreve came as a boon at the peak of the Delta wave in 2021. But as the injection turned ineffective against the Omicron variants, stocks piled up. While Novacare, the distributor, says Max defaulted on dues, the hospital group alleges misrepresentation in the matter. However, the dispute highlights larger issues regarding risks related to […]
PE firms in pink of health on improving returns from hospital investments.
Private equity investors have been investing large sums of money in hospitals. Certain types of hospital chains are delivering healthy returns for such investors.
How a genome map can help India fight cancer better
Genetic structure could hold some answers to the vexed issue of cancer. A reference set of genetic variants, specific to India’s diverse ethnic groups, can improve disease modelling and treatment.
